HalfLifeDBEvidence before certainty.

Alpha-PVP evidence profile

The study previously attached to this entry concerns alpha-PHiP, a different synthetic cathinone.

Category: stimulant · Updated: August 7, 2026

Sources and model notes are maintained by . This page is educational, not clinical guidance. Corrections: admin@halflifedb.co.

Model statusNo curve publishedCurrent sources do not support one defensible human input
Evidence boundarySource note onlyNo animal, forensic, mixture, or proxy value is presented as a human half-life
Model scopeNot modeledThe profile explains what the available records can and cannot establish
References2Linked studies, labels, reviews, or identity records described below

Alpha-PVP: evidence and interpretation notes

Why HalfLifeDB does not plot Alpha-PVP

The study previously attached to this entry concerns alpha-PHiP, a different synthetic cathinone. PubChem can confirm alpha-PVP identity, but neither record justifies assigning alpha-PVP a human half-life.

What each source contributes

  • PubChem: Alpha-PVP. This identity record confirms names and compound identity and does not supply a human half-life.
  • Disposition and effects of alpha-pyrrolidinoisohexanophenone (α-PHiP) in comparison with cocaine: an observational study. This human pharmacokinetic record adds measured route, analyte, and population context and does not become a universal result.

For Alpha-PVP, the decision to withhold a curve turns on the limits visible in Disposition and effects of alpha-pyrrolidinoisohexanophenone (α-PHiP) in comparison with cocaine: an observational study. This human pharmacokinetic record adds measured route, analyte, and population context, but it does not become a universal result.

What evidence would change the page

A defensible Alpha-PVP curve would require repeated human samples and a reported estimate for Alpha-PVP itself, rather than an inference from species, cases, related compounds, or class behavior. The current key record, Disposition and effects of alpha-pyrrolidinoisohexanophenone (α-PHiP) in comparison with cocaine: an observational study, answers a narrower question.

InterpretationCategory context and evidence limits

stimulant context

Stimulant half-life estimates can shift with urine pH, enzyme activity, formulation, dose, and whether metabolites are measured separately.

  • Alertness or subjective stimulation can end before modeled elimination.
  • Sleep disruption and downstream effects are not represented by the curve.
  • Formulation and route can change peak timing without changing the displayed model.
EvidenceSource trail and model decision

Sources and evidence context

A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.

1 PubMed0 PMC0 DailyMed1 PubChem
  1. Identity record PubChem Compound Summary: Alpha-PVP.
    Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
  2. Research abstract PubMed: Disposition and effects of alpha-pyrrolidinoisohexanophenone (α-PHiP) in comparison with cocaine: an observational study.
    Direct pharmacokinetic context. Population, route, formulation, analyte, and sampling duration still determine how broadly the result can be applied.
BoundariesWhat this page cannot answer and where to continue

What this page does not answer

  • It does not estimate impairment, intoxication, or fitness to drive.
  • It does not predict urine, blood, saliva, or hair test results.
  • It does not model repeated exposure, tolerance, withdrawal, or interactions.
  • It does not replace clinician, pharmacist, toxicologist, or emergency guidance.

Continue with context

Read the medical disclaimer, methodology, and research standards before using the model for comparison.